I-BI-1206 ngumgqatswa weyeza eliphambili le-BioInvent kwaye kungoku nje iphandwa kulingo lweSigaba 1/2 ezibini. Omnye uvavanya i-BI-1206 indibaniselwano kunye ne-rituximab yonyango lwe-Non-Hodgkin lymphoma, ebandakanya izigulane ezine-FL, i-MCL kunye ne-marginal zone lymphoma (MZL) eziye zabuyela emva okanye ezichasayo kwi-rituximab. Ulingo lwesibini lweSigaba se-1/2 luphanda i-BI-1206 ngokudibanisa ne-anti-PD1 yonyango i-Keytruda® (pembrolizumab) kwiithumba eziqinileyo.
UGqr. Wei-Wu He, uSihlalo weCASI, kunye ne-CEO uthe, “I-BioInvent isaqhubeka nokwenza inkqubela ngophuhliso kunye nesikhokelo solawulo se-BI-1206. Ukwamkelwa kwe-CTA e-China ngoDisemba ka-2021 kunye ne-FDA ye-Orphan Orphan Drug Designation yamva nje ibonisa amandla anamandla ale antibody yodidi lokuqala. I-CASI inamalungelo orhwebo aseTshayina e-BI-1026, kwaye iqela lethu lilungiselela isifundo seklinikhi saseTshayina. I-CASI kunye ne-BioInvent ngamaqabane angenamthungo kwaye banenjongo efanayo yokunceda izigulana ezinobuchwepheshe obutsha bomayeza.
INTO ONOKUYITHATHA KWELI NQAKU:
- One is evaluating the BI-1206 combination with rituximab for the treatment of Non-Hodgkin lymphoma, which includes patients with FL, MCL and marginal zone lymphoma (MZL) who have relapsed or are refractory to rituximab.
- The CTA approval in China in December 2021 and the recent FDA Orphan Drug Designation demonstrate the strong potential of this first-in-class antibody.
- A second Phase 1/2 trial is investigating BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors.
